Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Study sponsor: LB Pharmaceuticals Inc. · LBRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12-04Actual
Enrollment · participants359Actual
Source updated2025-10-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.